Binding of Trastuzumab to ErbB2 Is Inhibited by a High Pericellular Density of Hyaluronan

Journal of Histochemistry and Cytochemistry

Volumn 60, Issue 8, 2012, Pages 567-575

  Váradi, Tímea ^a   Mersich, Tamás ^b   Auvinen, Päivi ^c   Tammi, Raija ^d   Tammi, Markku ^d   Salamon, Ferenc ^b   Besznyák, István ^b   Jakab, Ferenc ^b   Baranyai, Zsolt ^b   Szöllosi, János ^a   Nagy, Peter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UZSOKI HOSPITAL   (Hungary)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

breast cancer; epitope masking; ErbB2; hyaluronan; trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HYALURONIC ACID; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CELL DENSITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PERICELLULAR DENSITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; METABOLISM; MIDDLE AGED; PROTEIN BINDING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EPITOPES; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HYALURONIC ACID; MIDDLE AGED; PROTEIN BINDING; RECEPTOR, ERBB-2;

EID: 84866783186     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155412448070     Document Type: Article

References (50)

1. Auvinen P,Tammi R,Parkkinen J,Tammi M,Agren U,Johansson R,Hirvikoski P,Eskelinen M,Kosma VM.Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival.Am J Pathol. 2000;156:529-536.
2. Barok M,Isola J,Pályi-Krekk Z,Nagy P,Juhász I,Vereb G,Kauraniemi P,Kapanen A,Tanner M,Szöllo{double acute}si J.Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.Mol Cancer Ther. 2007;6:2065-2072.
3. Bourguignon LY,Peyrollier K,Gilad E,Brightman A.Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to β-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.J Biol Chem. 2007;282:1265-1280.
4. Cho HS,Mason K,Ramyar KX,Stanley AM,Gabelli SB,Denney DW,Leahy DJ.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.Nature. 2003;421:756-760.
5. Clynes RA,Towers TL,Presta LG,Ravetch JV.Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nat Med. 2000;6:443-446.
6. Day AJ,Prestwich GD.Hyaluronan-binding proteins: tying up the giant.J Biol Chem. 2002;277:4585-4588.
7. Di Cosimo S,Baselga J.Targeted therapies in breast cancer: where are we now?.Eur J Cancer. 2008;44:2781-2790.
8. Di Cosimo S,Baselga J.Management of breast cancer with targeted agents: importance of heterogeneity.Nat Rev Clin Oncol. 2010;7:139-147.
9. Franklin MC,Carey KD,Vajdos FF,Leahy DJ,de Vos AM,Sliwkowski MX.Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.Cancer Cell. 2004;5:317-328.
10. Fukumura D,Jain RK.Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize.J Cell Biochem. 2007;101:937-949.
11. Gonzalez RC,Woods RE,Eddins SLDigital image processing using Matlab. Gonzalez RCWoods REEddins SL, ed. Upper Saddle River, NJ: Pearson Prentice Hall; 2004:378-425.
12. Hynes NE,MacDonald G.ErbB receptors and signaling pathways in cancer.Curr Opin Cell Biol. 2009;21:177-184.
13. Itano N,Kimata K.Altered hyaluronan biosynthesis in cancer progression.Semin Cancer Biol. 2008;18:268-274.
14. Izumi Y,Xu L,di Tomaso E,Fukumura D,Jain RK.Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-280.
15. Jain RK.Determinants of tumor blood flow: a review.Cancer Res. 1988;48:2641-2658.
16. Junttila TT,Akita RW,Parsons K,Fields C,Lewis Phillips GD,Friedman LS,Sampath D,Sliwkowski MX.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.Cancer Cell. 2009;15:429-440.
17. Lane HA,Motoyama AB,Beuvink I,Hynes NE.Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.Ann Oncol. 2001;12 (Suppl 1): S21-S22.
18. Lieleg O,Ribbeck K.Biological hydrogels as selective diffusion barriers.Trends Cell Biol. 2011;21:543-551.
19. Lower EE,Glass E,Blau R,Harman S.HER-2/neu expression in primary and metastatic breast cancer.Breast Cancer Res Treat. 2009;113:301-306.
20. Lo{double acute}rincz T,Tóth J,Badalian G,Tímár J,Szendro{double acute}i M.HER-2/neu genotype of breast cancer may change in bone metastasis.Pathol Oncol Res. 2006;12:149-152.
21. Misra S,Ghatak S,Toole BP.Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.J Biol Chem. 2005;280:20310-20315.
22. Molina MA,Codony-Servat J,Albanell J,Rojo F,Arribas J,Baselga J.Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.Cancer Res. 2001;61:4744-4749.
23. Mukohara T.Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.Cancer Sci. 2011;102:1-8.
24. Myers JL,Well AD,Lorch RF2010. Research design and statistical analysis. 3rd ed.New York: Routledge.New York: Routledge; 2010:.
25. Nagata Y,Lan KH,Zhou X,Tan M,Esteva FJ,Sahin AA,Klos KS,Li P,Monia BP,Nguyen NT, et al.PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell. 2004;6:117-127.
26. Nagy P,Bene L,Balázs M,Hyun WC,Lockett SJ,Chiang NY,Waldman F,Feuerstein BG,Damjanovich S,Szöllo{double acute}si J.EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements.Cytometry. 1998;32:120-131.
27. Nagy P,Friedländer E,Tanner M,Kapanen AI,Carraway KL,Isola J,Jovin TM.Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.Cancer Res. 2005;65:473-482.
28. Nahta R,Esteva FJ.Herceptin: mechanisms of action and resistance.Cancer Lett. 2006;232:123-138.
29. Pályi-Krekk Z,Barok M,Isola J,Tammi M,Szöllo{double acute}si J,Nagy P.Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.Eur J Cancer. 2007;43:2423-2433.
30. Pályi-Krekk Z,Barok M,Kovács T,Saya H,Nagano O,Szöllo{double acute}si J,Nagy P.EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.Cancer Lett. 2008;263:231-242.
31. Pentassuglia L,Sawyer DB.The role of Neuregulin-1beta/ErbB signaling in the heart.Exp Cell Res. 2009;315:627-637.
32. Rilla K,Tiihonen R,Kultti A,Tammi M,Tammi R.Pericellular hyaluronan coat visualized in live cells with a fluorescent probe is scaffolded by plasma membrane protrusions.J Histochem Cytochem. 2008;56:901-910.
33. Ross JS,Fletcher JA,Linette GP,Stec J,Clark E,Ayers M,Symmans WF,Pusztai L,Bloom KJ.The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist. 2003;8:307-325.
34. Sironen RK,Tammi M,Tammi R,Auvinen PK,Anttila M,Kosma VM.Hyaluronan in human malignancies.Exp Cell Res. 2011;317:383-391.
35. Smith I,Procter M,Gelber RD,Guillaume S,Feyereislova A,Dowsett M,Goldhirsch A,Untch M,Mariani G,Baselga J, et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Lancet. 2007;369:29-36.
36. Sperinde J,Jin X,Banerjee J,Penuel E,Saha A,Diedrich G,Huang W,Leitzel K,Weidler J,Ali SM, et al.Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.Clin Cancer Res. 2010;16:4226-4235.
37. Storr SJ,Woolston CM,Barros FF,Green AR,Shehata M,Chan SY,Ellis IO,Martin SG.Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy.Int J Cancer. 2011;129:1773-1780.
38. Takahashi Y,Li L,Kamiryo M,Asteriou T,Moustakas A,Yamashita H,Heldin P.Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GR01-dependent manner.J Biol Chem. 2005;280:24195-24204.
39. Tammi R,Ripellino JA,Margolis RU,Tammi M.Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe.J Invest Dermatol. 1988;90:412-414.
40. Thompson CB,Shepard HM,O'Connor PM,Kadhim S,Jiang P,Osgood RJ,Bookbinder LH,Li X,Sugarman BJ,Connor RJ, et al.Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.Mol Cancer Ther. 2010;9:3052-3064.
41. Toole BP.Hyaluronan: from extracellular glue to pericellular cue.Nat Rev Cancer. 2004;4:528-539.
42. Toole BP,Wight TN,Tammi MI.Hyaluronan-cell interactions in cancer and vascular disease.J Biol Chem. 2002;277:4593-4596.
43. Toole BP,Zoltan-Jones A,Misra S,Ghatak S.Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs. 2005;179:66-72.
44. Twarock S,Freudenberger T,Poscher E,Dai G,Jannasch K,Dullin C,Alves F,Prenzel K,Knoefel WT,Stoecklein NH, et al.Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis.Mol Cancer. 2011;10:30.
45. Udabage L,Brownlee GR,Waltham M,Blick T,Walker EC,Heldin P,Nilsson SK,Thompson EW,Brown TJ.Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer.Cancer Res. 2005;65:6139-6150.
46. Urakawa H,Nishida Y,Wasa J,Arai E,Zhuo L,Kimata K,Kozawa E,Futamura N,Ishiguro N.Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo.Int J Cancer. 2012;130:454-466.
47. van der Vegt B,de Bock GH,Bart J,Zwartjes NG,Wesseling J.Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.Mod Pathol. 2009;22:879-886.
48. Weigel PH,DeAngelis PL.Hyaluronan synthases: a decade-plus of novel glycosyltransferases.J Biol Chem. 2007;282:36777-36781.
49. Weinstein IB,Joe A.Oncogene addiction.Cancer Res. 2008;68:3077-3080.
50. Wernicke M,Pineiro LC,Caramutti D,Dorn VG,Raffo MM,Guixa HG,Telenta M,Morandi AA.Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan.Mod Pathol. 2003;16:99-107.